Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has signed a tripartite agreement with Hangzhou Aomei Pharmaceutical Co., Ltd. and Aspen (Guang Dong) Pharmaceutical Co., Ltd. for the exclusive marketing of the drug Agerglucoside Sodium Injection in mainland China, indicating a strategic move towards commercialization of the product [1][2][12]. Group 1: Agreement Details - The tripartite agreement allows Aspen to act as the exclusive marketing service provider for Agerglucoside Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [2][8]. - The commercialization milestone sharing agreement stipulates a 50% split of milestone payments and net sales revenue between Xianju Pharmaceutical and Aomei Pharmaceutical after deducting relevant costs [2][10]. - Additional agreements include a raw material supply agreement and a contract for commissioned production of Agerglucoside Sodium Injection, ensuring a stable supply and quality assurance for the product [3][10]. Group 2: Company Background - Hangzhou Aomei Pharmaceutical Co., Ltd. was established on October 25, 2000, with a registered capital of 69.825291 million RMB, focusing on medical research, chemical product sales, and drug production [4][5]. - Aspen (Guang Dong) Pharmaceutical Co., Ltd. was founded on January 31, 1997, with a registered capital of 57.6 million USD, specializing in the wholesale and production of various pharmaceutical products [5][6]. Group 3: Impact on Company - The signing of these agreements is a preparatory step for the future commercialization of Agerglucoside Sodium Injection, leveraging Aspen's extensive market experience in the anesthesia field to enhance product promotion and sales [12]. - The agreements clarify the revenue distribution and supply assurance mechanisms for the product post-approval, which is beneficial for the product's market entry and aligns with the interests of the company and its shareholders [12][13].

Core Viewpoint - Xianju Pharmaceutical has established strategic partnerships for the development and commercialization of the drug Aomikson Sodium (also known as Ageng Glucose Sodium Injection) with Hangzhou Aomei Pharmaceutical and Aishijian (Guangdong) Pharmaceutical [1][2] Group 1: Agreements and Collaborations - On December 17, 2015, Xianju Pharmaceutical signed a development cooperation agreement for Aomikson Sodium with Hangzhou Aomei [1] - A supplementary agreement was signed on April 16, 2021, to further the development of Aomikson Sodium [1] - A strategic cooperation framework agreement was signed on January 12, 2023, to outline the collaboration on Aomikson Sodium [1] Group 2: Recent Developments - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian signed a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Aomikson Sodium in mainland China [2] - The commercialization milestone sharing ratio for Aomikson Sodium is set at 50% for both Xianju Pharmaceutical and Hangzhou Aomei [2] - A procurement supply agreement and a supplementary agreement for contract manufacturing of Aomikson Sodium were also signed on January 16, 2026 [2]

Core Viewpoint - Xianju Pharmaceutical has entered into a tripartite agreement with Hangzhou Aomei and Aishijian for the exclusive marketing of Ageng Glucosamine Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The agreement designates Aishijian as the exclusive marketing service provider for Ageng Glucosamine Sodium Injection in mainland China [1] - Xianju Pharmaceutical and Hangzhou Aomei have established a milestone revenue-sharing agreement, with both parties sharing 50% of the commercialization milestone revenue [1] - The net revenue from commercialization sales in mainland China will also be shared equally, with both companies receiving 50% after deducting relevant expenses [1] Group 2 - Xianju Pharmaceutical and Hangzhou Aomei have signed a procurement supply agreement for the raw materials of Ageng Glucosamine Sodium and a supplementary agreement for the commissioned production of the injection [1] - Ageng Glucosamine Sodium Injection is classified as a Class 1 new drug and is a targeted muscle relaxant [1]

Core Viewpoint - The collaboration between Xianju Pharmaceutical and Hangzhou Aomei Pharmaceutical focuses on the development, production, and commercialization of the drug Aomeikongsu Sodium (also known as Ageng Glucose Sodium Injection) [1][2] Group 1: Agreements and Collaborations - Xianju Pharmaceutical signed multiple agreements with Hangzhou Aomei, including the initial development cooperation agreement in December 2015, a supplementary agreement in April 2021, and a strategic cooperation framework agreement in January 2023 [1] - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian (Guangdong) Pharmaceutical Co., Ltd. entered into a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Ageng Glucose Sodium Injection in mainland China [2] - The commercialization milestone sharing agreement and sales revenue sharing agreement stipulate that both Xianju Pharmaceutical and Hangzhou Aomei will share 50% of the commercialization milestones and net sales revenue after deducting relevant expenses [2] Group 2: Product Naming and Regulatory Aspects - The Chinese common name for Aomeikongsu Sodium and its injection form is officially recognized as Ageng Glucose Sodium and Ageng Glucose Sodium Injection, respectively [1] - The agreements outline specific terms regarding the procurement of raw materials and contract manufacturing for Ageng Glucose Sodium Injection [2]

证券代码：002332 证券简称：仙琚制药 公告编号：2026-003 浙江仙琚制药股份有限公司 关于签订共同授权合作产品中国境内推广服务之三方协议 及相关协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"、"仙琚制药"）与杭州奥默医 药股份有限公司（以下简称"杭州奥默"）于2015年12月17日签署了《1.1类新药奥 美克松钠产品开发合作协议》（公告编号：2015-058）、2021年4月16日签署了《1.1 类新药奥美克松钠产品开发合作协议》之补充协议（公告编号：2021-014）、2023年 1月12日签署了《1.1类新药靶向性肌松拮抗剂奥美克松钠产品战略合作框架协议》等 相关协议（"原协议"），就奥美克松钠（阿更葡糖钠注射液）（以下简称"合作产 品"）的研发、生产及商业化合作达成各项约定。 根据国家药典委员会2025年10月《关于申报奥美克松钠产品通用名称的函》："奥 美克松钠"、"奥美克松钠注射液"，中文通用名称为"阿更葡糖钠"、"阿更葡糖 钠注射液"。以下各协议中的"奥美克松钠注射液"均指"阿更葡 ...

Group 1 - The company has announced a partnership with Hangzhou Aomei Pharmaceutical Co., Ltd. to jointly authorize Aishijian (Guangdong) Pharmaceutical Co., Ltd. as the exclusive marketing service provider for Agomelatine injection in mainland China (excluding Hong Kong, Macau, and Taiwan) [1] - A milestone revenue-sharing agreement and sales revenue-sharing agreement have been signed, with both parties agreeing to share commercial revenue equally at 50% [1] - Additionally, a raw material procurement supply agreement and a supplementary contract for commissioned processing production have been established [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2026-002 浙江仙琚制药股份有限公司 关于子公司收到保险赔付的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）的全资子公司Newchem S.P.A （以下简称"Newchem公司"）近日收到有关《保险赔付确认函》，本次保险赔付确 认函新确认的保险赔付金额为920万欧元（含第三方鉴定费用20万欧元），2025年2月 已收到保险赔款450万欧元，保险公司最终确认的保险赔付金额为1370万欧元。 Newchem 公司位于意大利维罗纳厂区的一处烘箱干燥区域于2024年6月26日发生 意外火灾事故，致该部分区域设备设施损毁，无人员伤亡。受损区域已完成重建并已 经重新投入运行。 该火灾事故发生于2024年6月26日晚上20点左右，车间员工在对烘箱进行清洁时 突然发生起火，火势蔓延到了相邻区域和设备。现场出现火情后，车间员工在第一时 间上报当地消防部门，消防部门和公司应急小组协同完成了灭火工作。火灾造成4台 烘箱及周边部分设备设施损毁，无人员伤亡。 Newchem ...

Core Viewpoint - Newchem S.P.A, a wholly-owned subsidiary of Xianju Pharmaceutical, has received an insurance compensation confirmation letter for a total amount of €9.2 million, which includes €200,000 for third-party assessment fees, following a fire incident at its facility in Verona, Italy [1] Group 1 - The fire incident occurred on June 26, 2024, damaging equipment in the drying area, but there were no casualties reported [1] - The total confirmed insurance compensation amount by the insurance company is €13.7 million, of which €4.5 million was received in February 2025 [1] - The damaged area has been rebuilt and is now back in operation [1] Group 2 - The company received the new insurance compensation payment of €9.2 million on January 13, 2026 [1] - According to preliminary financial confirmations, this compensation is expected to have a certain impact on the company's profits for the fiscal year 2025, with specific effects to be detailed in the annual audit report [1]

Core Viewpoint - The company emphasizes its commitment to innovation and breakthroughs in both raw materials and formulation development, focusing on high-tech areas and clinical needs [1] Group 1: Raw Material Development - The company aims to upgrade processes and achieve breakthroughs in high-tech fields such as sterility and crystal size [1] Group 2: Formulation Innovation - The company plans to initiate projects for modified new drugs and explore innovative targets based on clinical needs and disease mechanisms [1] Group 3: Innovation Process - The company views innovation as a continuous process of experimentation and iteration [1]

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]